Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Kura Oncology Inc (NASDAQ: KURA) closed the day trading at $7.27 down -0.95% from the previous closing price of $7.34. In other words, the price has decreased by -$0.95 from its previous closing price. On the day, 0.69 million shares were traded. KURA stock price reached its highest trading level at $7.38 during the session, while it also had its lowest trading level at $7.14.
Ratios:
For a better understanding of KURA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.39. For the most recent quarter (mrq), Quick Ratio is recorded 9.46 and its Current Ratio is at 9.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.
Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 28 ’25 when DOYLE THOMAS JAMES sold 4,949 shares for $7.87 per share. The transaction valued at 38,958 led to the insider holds 88,193 shares of the business.
Leoni Mollie sold 4,963 shares of KURA for $39,068 on Jan 28 ’25. The Chief Medical Officer now owns 88,253 shares after completing the transaction at $7.87 per share. On Jan 28 ’25, another insider, Bair Teresa Brophy, who serves as the Chief Legal Officer of the company, sold 7,281 shares for $7.87 each. As a result, the insider received 57,315 and left with 107,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 587088832 and an Enterprise Value of -123712432. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.90 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at -2.296 whereas that against EBITDA is 0.643.
Stock Price History:
The Beta on a monthly basis for KURA is 0.77, which has changed by -0.65948474 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $23.48, while it has fallen to a 52-week low of $6.79. The 50-Day Moving Average of the stock is -7.21%, while the 200-Day Moving Average is calculated to be -52.27%.
Shares Statistics:
Over the past 3-months, KURA traded about 1.59M shares per day on average, while over the past 10 days, KURA traded about 1274330 shares per day. A total of 78.23M shares are outstanding, with a floating share count of 75.15M. Insiders hold about 6.94% of the company’s shares, while institutions hold 96.08% stake in the company. Shares short for KURA as of 1740700800 were 9211838 with a Short Ratio of 5.78, compared to 1738281600 on 8075542. Therefore, it implies a Short% of Shares Outstanding of 9211838 and a Short% of Float of 11.5200005.
Earnings Estimates
A detailed examination of Kura Oncology Inc (KURA) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.07 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$0.28 and -$3.14 for the fiscal current year, implying an average EPS of -$2.12. EPS for the following year is -$2.05, with 10.0 analysts recommending between $0.95 and -$4.79.
Revenue Estimates
Based on 14 analysts’ estimates, the company’s revenue will be $184.33M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
